Lenvatinib Mesylate Intermedia CAS 15568-85-1 Puritas >97.0% (HPLC) Factory

Description:

5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione

CAS: 15568-85-1

Puritas: >97.0% (HPLC)

Aspectus: Yellow pulveris

Medium de Lenvatinib Mesylate CAS 857890-39-2

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4

Chemical Properties:

Nomen chemicum	5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione
Synonyma	5-(Methoxymethylene) Meldrum's Acidum;Cabozantinib Impuritas 56;Lenvatinib immunditia 79
CAS Number	15568-85-1
CATTUS Number	RF-PI1967
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C8H10O5
M. Pondus	186.16
Liquescens punctum	132.0~ 134.0℃
Density	1.297±0.06 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Flavus pulveris
1 H NMR Spectrum	Congruunt cum Structure
Puritas / Analysis Methodus	>97.0% (HPLC)
Totalis immunditias	<3.00%
Test Standard	Enterprise Standard
Consuetudinem	Medium de Mesylate Lenvatinib (CAS: 857890-39-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS:15568-85-1) media est Mesylate Lenvatinib (CAS: 857890-39-2).Lenvatinib est medicamentum thyreoidum pharmacum ab Eisai Corporatione Iaponiae (Codex: E7080) inhibitoris multi-receptoris tyrosini kinasi (RTK) inhibitoris pertinens ac kinasum activitatem endothelialem factoris (VEGF) receptoribus VEGFR1 inhibere potest. FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).Lenvatinib etiam impedire potest implicationem aliorum RTKs in angiogenesi pathologica, tumore augmento, et progressu cancri, exceptis functionibus normalibus cellularum inclusis fibroblast aucti (FGF) receptores FGFR1, II, III, IV;factor augmentationis receptae (PDGFR [alpha]), KIT, RET.[Indicationes]: Lenvatinib apta est curatione aegrorum cancri thyroideae localis recursu vel metastasi speciei, progressionis generis et iodi-refractionis radioactivi speciei differentiatae.Die 13 Februarii 2015, US FDA approbavit anticancer medicamentum Lenvatinib ad curationem cancri thyreici.Lenvatinib inhibitor enzyme multiplex est, cum possit inhibere VEGFR2 et VEGFR3 (vascularis incrementi endothelialis factor receptor).Nomen artis Lenvatinib est Lenvima.Die XX mensis Maii anno MMXV, Medicinae Europaeae Agency (EMA) Lenvatinib approbavit ad curationem incursionis, localiter progressae vel metastaticae differentiatae (papillaris, follicularis, generis Hurthle) cancri thyreici (DTC).In iudicio, media salus tempus aegris radioactivi Iodi-refractionis DTC tractatum cum Lenvatinib fuit XVIII mensium, dum valor aegrorum qui placebo capiuntur tantum 3 mensium est.